Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases
Authors
Keywords
-
Journal
NEURO-ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2015-02-14
DOI
10.1093/neuonc/nov012
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
- (2014) S. M. Swain et al. ANNALS OF ONCOLOGY
- Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
- (2014) Huan Cheng et al. BMC CANCER
- Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff
- (2014) R. Duchnowska et al. CLINICAL CANCER RESEARCH
- High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
- (2014) Maurizio Scaltriti et al. CLINICAL CANCER RESEARCH
- Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy
- (2014) Josep Lluís Parra-Palau et al. JNCI-Journal of the National Cancer Institute
- Constitutive HER2 Signaling Promotes Breast Cancer Metastasis through Cellular Senescence
- (2013) P. D. Angelini et al. CANCER RESEARCH
- Progress in the Biological Understanding and Management of Breast Cancer-Associated Central Nervous System Metastases
- (2013) S. Dawood et al. ONCOLOGIST
- Discordances in Estrogen Receptor Status, Progesterone Receptor Status, and HER2 Status Between Primary Breast Cancer and Metastasis
- (2013) E. Curtit et al. ONCOLOGIST
- Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer
- (2012) A. Jo Chien et al. BREAST CANCER RESEARCH AND TREATMENT
- Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer
- (2012) Shaheenah Dawood et al. CANCER
- Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
- (2012) Linda Sofie Lindström et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
- (2012) Thomas Bachelot et al. LANCET ONCOLOGY
- Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation and is associated with loss of phosphorylated STAT5
- (2012) T M Ward et al. ONCOGENE
- Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors
- (2011) Naoki Niikura et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Central HER2 Testing With Quantitative Total HER2 Expression and HER2 Homodimer Measurements Using a Novel Proximity-Based Assay
- (2010) Weidong Huang et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- HER2 status in a population-derived breast cancer cohort: discordances during tumor progression
- (2010) Ulla Wilking et al. BREAST CANCER RESEARCH AND TREATMENT
- Stability of estrogen receptor status in breast carcinoma
- (2010) Yun Gong et al. CANCER
- Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer
- (2010) Antonino Musolino et al. CANCER
- A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-modulation of the Estrogen Receptor in HER2-Positive Breast Cancers
- (2010) J. L. Parra-Palau et al. CANCER RESEARCH
- Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor
- (2010) M. Scaltriti et al. CLINICAL CANCER RESEARCH
- Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients
- (2010) J. Sperinde et al. CLINICAL CANCER RESEARCH
- Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer
- (2009) C. Liedtke et al. ANNALS OF ONCOLOGY
- A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis
- (2009) K. Pedersen et al. MOLECULAR AND CELLULAR BIOLOGY
- Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer
- (2008) I. H. Park et al. ANNALS OF ONCOLOGY
- Immunohistochemical profiles of brain metastases from breast cancer
- (2008) Kan Yonemori et al. JOURNAL OF NEURO-ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started